Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
A 2021 study in Obesity found that combining behavioural intervention with pharmacotherapy produced greater weight loss and better maintenance than either approach alone
Our Semaglutide and Tirzepatide weight loss programs offer a modern solution for patients ready to take control of their health with expert guidance
Some insurance plans may cover GLP-1 medications, and we assist with benefit checks and prior authorizations
MASLD Substudy Sanyal et al., Nature Medicine (2024) Sanyal and colleagues conducted a prespecified phase 2a substudy of the original phase 2 obesity trial, evaluating retatrutide in participants with metabolic dysfunction-associated steatotic liver disease (MASLD)
Nadolsky KZ et al
/assets/images/provider/photos/2774234.jpeg)
/assets/images/provider/photos/2707250.jpeg)
US$ 28.33
US$ 26.41
US$ 23.74
US$ 26.81
